BRD9 and cancer: Therefore, although studies indicate that BRD9 inhibitors abrogate tumorigenicity in diverse cancer types, because the drugs differ in their selectivity, confirmation of the target via genetic depletion is crucial to understand drug mechanism in a particular cellular context.